Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Add Yahoo as a preferred source to see more of our stories on Google. A new drug could halt the progression of Alzheimer’s disease. Trials suggest the treatment, called trontinemab, could be the most ...

The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering ...

With few treatments available to stop or reverse Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of walking back cognitive decline. Alzheimer’s cases are rising in the ...

The U.K.’s national health spending watchdog will reevaluate its decision to exclude the use of two Alzheimer’s drugs ...

Old drugs, new ideas. That’s one of the core drivers of using artificial intelligence (AI) for drug development. Researchers using complex AI-fueled methods are now taking aim at what has become a ...

Coleman's global leadership and deep expertise across philanthropy, private sector, and public service position the ADDF to define the next phase of Alzheimer's science NEW YORK, March 11, 2026 ...